IA
CLRB icon

Independence Advisors’s Cellectar Biosciences CLRB Stock Holding History

Independence Advisors’s Portfolio CLRB Stock Details CLRB Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		$12K Hold
33
– – ﹤0.01% 147
2020
Q2 		$13K Buy
+33
New +$13.9K ﹤0.01% 140

Other funds holding CLRB

SCM
Sio Capital Management New York $697M AUM 79.73% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
FIA
FNY Investment Advisers New York $278M AUM 98.95% 1-Year Est. Return
WVP
Worth Venture Partners Fort Lee, New Jersey $31.6M AUM 28.5% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
QP
Quilter Plc London, United Kingdom $5.7B AUM 21.25% 1-Year Est. Return
WS
Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Independence Advisors's CLRB Position: Q3 2020 in Review

Independence Advisors held its Cellectar Biosciences (CLRB) position steady in Q3 2020 at 33 shares worth $12K. The position accounts for ﹤0.01% of the portfolio, ranked #147.

Independence Advisors first reported a position in CLRB in Q2 2020 and has held it in 2 quarters since. The position peaked at $13K in Q2 2020. 20 funds tracked by Wall St. Rank hold CLRB as of Q3 2020.

  • Independence Advisors held 33 shares of Cellectar Biosciences worth $12K as of Q3 2020.
  • Independence Advisors left its Cellectar Biosciences share count unchanged in Q3 2020.
  • Cellectar Biosciences made up ﹤0.01% of Independence Advisors's portfolio in Q3 2020, its #147 holding.
  • Independence Advisors first reported a position in Cellectar Biosciences in Q2 2020 and has held it in 2 quarters since.
  • Independence Advisors's Cellectar Biosciences position peaked at $13K in Q2 2020.
  • 20 funds tracked by Wall St. Rank held Cellectar Biosciences as of Q3 2020.

Based on Independence Advisors's 13F filing for Q3 2020, filed 4 Nov 2020.